Plato Investment Management Ltd Decreases Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)

Plato Investment Management Ltd trimmed its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 58.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 498 shares of the company’s stock after selling 688 shares during the period. Plato Investment Management Ltd’s holdings in Janux Therapeutics were worth $27,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of JANX. Avanza Fonder AB acquired a new stake in shares of Janux Therapeutics during the fourth quarter worth about $139,000. Chicago Capital LLC acquired a new stake in shares of Janux Therapeutics during the fourth quarter worth about $230,000. Chicago Partners Investment Group LLC acquired a new stake in shares of Janux Therapeutics during the third quarter worth about $239,000. Legato Capital Management LLC acquired a new stake in shares of Janux Therapeutics during the fourth quarter worth about $347,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Janux Therapeutics during the third quarter worth about $317,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on JANX. BTIG Research lifted their target price on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $200.00 target price on shares of Janux Therapeutics in a research report on Wednesday, December 11th. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating and issued a $70.00 price target on shares of Janux Therapeutics in a research report on Monday. Finally, Stifel Nicolaus boosted their price target on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $88.00.

Janux Therapeutics Trading Up 5.0 %

NASDAQ JANX opened at $31.50 on Thursday. The business’s 50 day moving average is $42.23 and its two-hundred day moving average is $47.67. Janux Therapeutics, Inc. has a 12-month low of $29.63 and a 12-month high of $71.71. The stock has a market capitalization of $1.65 billion, a price-to-earnings ratio of -26.92 and a beta of 3.16.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Equities analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Insider Transactions at Janux Therapeutics

In other news, CEO David Alan Campbell sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 24th. The stock was sold at an average price of $56.19, for a total transaction of $1,404,750.00. Following the sale, the chief executive officer now owns 217,054 shares of the company’s stock, valued at $12,196,264.26. The trade was a 10.33 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Andrew Hollman Meyer sold 13,334 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $54.88, for a total value of $731,769.92. Following the sale, the insider now directly owns 82,139 shares in the company, valued at $4,507,788.32. This trade represents a 13.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 50,002 shares of company stock valued at $2,684,703 in the last quarter. 29.40% of the stock is currently owned by corporate insiders.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.